Please assess the completion status of the following clinical trial:

Trial Title: The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 18 years and \< 65 years who present with an acute episode of TTP~* Evidence of microangiopathic haemolytic anaemia~* Thrombocytopenia with a normal clotting screen~* Raised Lactate Dehydrogenase (one and a half time above upper normal)~* Patients without neurological dysfunction able to give informed consent~* Patients of reproductive age (must avoid pregnancy for 12 months and/or normalised B cell function after receiving Rituximab. Oestrogen containing oral contraceptive pills and the morning after pills should be avoided in female TTP patients)~* Patients with an acute deterioration in neurological function which may include encephalopathy, such as altered personality, problems with short term memory and coma can be included when consent has been given by next of kin or from the appropriate legal representative.~Exclusion Criteria:~* All female subjects who are knowingly pregnant or breast feeding or do not use an adequate form of contraception (the effect on the foetus and newborn have not yet been fully established so Rituximab should be avoided in these groups. Male patients receiving Rituximab should ensure adequate contraception for 12 months following treatment).~* Patients who are HIV positive (which does not appear to be antibody mediated, would be unlikely to benefit from Rituximab)~* Patients with childhood TTP~* Patients who have Haemolytic Uraemic Syndrome (HUS) (which is not associated with reduced ADAMTS 13 levels)~* Patients who are post bone marrow transplant - either autologous or allogeneic~* Patients wiht a medical or long term psychiatric condition which, in the opinion of the investigator, contraindicates the patients' participation into the trial~* Previous or concurrent malignancies at other sites, with exception of appropriately treated localized epithelial or cervical cancer. Patients with a history of cured tumours may be entered (\> 5 years).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- no comparator (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).